On the other hand, in the ABCSG-18 study including 3,425 postmenopausal women with estrogen receptor-positive or progesterone receptor-positive early breast cancer, adjuvant denosumab therapy delayed the disease recurrence in postmenopausal patients with early-stage lower-risk breast cancer (180). Here, PGR is linked to breast carcinoma.